Skip to content
Biodatica
Start free

Novartis Pharmaceuticals

Konstanz, Baden-Wurttemberg

OncologyFiled/ApprovedListed · NVS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

1w agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Mar 18, 2026

    Heart Failure With Reduced Ejection Fraction · RECRUITING · sponsor: Novartis Pharmaceuticals · A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

    ClinicalTrials.gov · NCT07465653 (opens the source filing in a new tab)

  2. Trial

    PHASE4 registered

    Nov 26, 2025

    Atherosclerotic Cardiovascular Disease · RECRUITING · sponsor: Novartis Pharmaceuticals · Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

    ClinicalTrials.gov · NCT07034690 (opens the source filing in a new tab)

  3. Trial

    PHASE4 registered

    Jun 17, 2025

    Coronary Heart Disease · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

    ClinicalTrials.gov · NCT06941792 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Sep 4, 2024

    Metastatic Castration Resistant Prostate Cancer · RECRUITING · sponsor: Novartis Pharmaceuticals · Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

    ClinicalTrials.gov · NCT06517719 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Sep 4, 2024

    Prostate Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

    ClinicalTrials.gov · NCT07477756 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Jun 11, 2024

    Chronic Spontaneous Urticaria · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany

    ClinicalTrials.gov · NCT06991608 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Dec 12, 2023

    Heart Failure · TERMINATED · sponsor: Novartis Pharmaceuticals · A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

    ClinicalTrials.gov · NCT06142383 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Oct 26, 2022

    Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

    ClinicalTrials.gov · NCT05544929 (opens the source filing in a new tab)

  9. Trial

    PHASE4 registered

    Feb 11, 2022

    Fascioliasis · COMPLETED · sponsor: Novartis Pharmaceuticals · Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

    ClinicalTrials.gov · NCT04230148 (opens the source filing in a new tab)

  10. Trial

    PHASE2 registered

    Nov 15, 2021

    Metastatic Colorectal Cancer · TERMINATED · sponsor: Novartis Pharmaceuticals · Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

    ClinicalTrials.gov · NCT04952753 (opens the source filing in a new tab)

  11. Trial

    PHASE4 registered

    Jul 13, 2021

    Age-related Macular Degeneration · COMPLETED · sponsor: Novartis Pharmaceuticals · Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

    ClinicalTrials.gov · NCT04679935 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources